{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T20:19:55Z","timestamp":1780345195640,"version":"3.54.1"},"reference-count":46,"publisher":"American Association for Cancer Research (AACR)","issue":"11","funder":[{"name":"Hagar Family Foundation"},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"publisher","award":["W81XWH1810287"],"award-info":[{"award-number":["W81XWH1810287"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"publisher","award":["U54 CA196519"],"award-info":[{"award-number":["U54 CA196519"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Loss of the tumor suppressor NF1 leads to activation of RAS effector pathways, which are therapeutically targeted by inhibition of mTOR (mTORi) or MEK (MEKi). However, therapeutic inhibition of RAS effectors leads to the development of drug resistance and ultimately disease progression. To investigate molecular signatures in the context of NF1 loss and subsequent acquired drug resistance, we analyzed the exomes, transcriptomes, and kinomes of Nf1-mutant mouse tumor cell lines and derivatives of these lines that acquired resistance to either MEKi or mTORi. Biochemical comparisons of this unique panel of tumor cells, all of which arose in Nf1+\/\u2212 mice, indicate that loss of heterozygosity of Nf1 as an initial genetic event does not confer a common biochemical signature or response to kinase inhibition. Although acquired drug resistance by Nf1-mutant tumor cells was accompanied by altered kinomes and irreversibly altered transcriptomes, functionally in multiple Nf1-mutant tumor cell lines, MEKi resistance was a stable phenotype, in contrast to mTORi resistance, which was reversible. Collectively, these findings demonstrate that Nf1-mutant tumors represent a heterogeneous group biochemically and undergo broader remodeling of kinome activity and gene expression in response to targeted kinase inhibition.<\/jats:p>","DOI":"10.1158\/1535-7163.mct-19-1017","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T17:10:40Z","timestamp":1598461840000},"page":"2382-2395","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["<i>Nf1<\/i>\n                    -Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK"],"prefix":"10.1158","volume":"19","author":[{"given":"Daniela","family":"Pucciarelli","sequence":"first","affiliation":[{"name":"1Department of Radiation Oncology, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7655-657X","authenticated-orcid":false,"given":"Steven P.","family":"Angus","sequence":"additional","affiliation":[{"name":"2Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6996-0833","authenticated-orcid":false,"given":"Benjamin","family":"Huang","sequence":"additional","affiliation":[{"name":"3Department of Pediatrics, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9553-0925","authenticated-orcid":false,"given":"Chi","family":"Zhang","sequence":"additional","affiliation":[{"name":"4Department of Pediatrics, Indiana University, Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki J.","family":"Nakaoka","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Krishnamurthi","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3120-923X","authenticated-orcid":false,"given":"Sourav","family":"Bandyopadhyay","sequence":"additional","affiliation":[{"name":"5Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Wade","family":"Clapp","sequence":"additional","affiliation":[{"name":"4Department of Pediatrics, Indiana University, Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Shannon","sequence":"additional","affiliation":[{"name":"3Department of Pediatrics, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2867-0551","authenticated-orcid":false,"given":"Gary L.","family":"Johnson","sequence":"additional","affiliation":[{"name":"2Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean L.","family":"Nakamura","sequence":"additional","affiliation":[{"name":"1Department of Radiation Oncology, University of California San Francisco, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2020,11,3]]},"reference":[{"key":"2022060801065693100_bib1","doi-asserted-by":"crossref","first-page":"8322","DOI":"10.1158\/0008-5472.CAN-07-6720","article-title":"Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors","volume":"68","author":"Buck","year":"2008","journal-title":"Cancer Res"},{"key":"2022060801065693100_bib2","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1158\/1535-7163.MCT-10-1033","article-title":"Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancer","volume":"10","author":"Gioeli","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"2022060801065693100_bib3","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/1878-0261.12102","article-title":"MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701","volume":"11","author":"Chen","year":"2017","journal-title":"Mol Oncol"},{"key":"2022060801065693100_bib4","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1158\/1535-7163.MCT-18-0727","article-title":"Differences in signaling patterns on PI3K inhibition reveal context specificity in KRAS-mutant cancers","volume":"18","author":"Stewart","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"2022060801065693100_bib5","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrc3911","article-title":"A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor","volume":"15","author":"Ratner","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"2022060801065693100_bib6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40246-017-0109-3","article-title":"The NF1 somatic mutational landscape in sporadic human cancers","volume":"11","author":"Philpott","year":"2017","journal-title":"Hum Genomics"},{"key":"2022060801065693100_bib7","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1535-7163.MCT-07-0518","article-title":"Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells","volume":"7","author":"Ambrosini","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"2022060801065693100_bib8","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1172\/JCI60578","article-title":"MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors","volume":"123","author":"Jessen","year":"2013","journal-title":"J Clin Invest"},{"key":"2022060801065693100_bib9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1172\/JCI66167","article-title":"Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk","volume":"123","author":"Staser","year":"2013","journal-title":"J Clin Invest"},{"key":"2022060801065693100_bib10","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/ajmg.a.61485","article-title":"Advancing RAS\/RASopathy therapies: An NCI-sponsored intramural and extramural collaboration for the study of RASopathies","volume":"182","author":"Gross","year":"2020","journal-title":"Am J Med Genet A"},{"key":"2022060801065693100_bib11","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1158\/2159-8290.CD-14-0159","article-title":"Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers","volume":"4","author":"Malone","year":"2014","journal-title":"Cancer Discov"},{"key":"2022060801065693100_bib12","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S1470-2045(12)70414-X","article-title":"Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial","volume":"13","author":"Robertson","year":"2012","journal-title":"Lancet Oncol"},{"key":"2022060801065693100_bib13","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/0008-5472.CAN-10-2732","article-title":"Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice","volume":"71","author":"Nakamura","year":"2011","journal-title":"Cancer Res"},{"key":"2022060801065693100_bib14","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.1158\/0008-5472.CAN-12-1728","article-title":"Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms","volume":"72","author":"Choi","year":"2012","journal-title":"Cancer Res"},{"key":"2022060801065693100_bib15","doi-asserted-by":"crossref","first-page":"e1005235","DOI":"10.1371\/journal.pgen.1005235","article-title":"Monoallelic loss of the imprinted gene Grb10 promotes tumor formation in irradiated Nf1\u00b1 mice","volume":"11","author":"Mroue","year":"2015","journal-title":"PLoS Genet"},{"key":"2022060801065693100_bib16","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1242\/jcs.182873","article-title":"RAS isoforms and mutations in cancer at a glance","volume":"129","author":"Hobbs","year":"2016","journal-title":"J Cell Sci"},{"key":"2022060801065693100_bib17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cell.2012.02.053","article-title":"Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer","volume":"149","author":"Duncan","year":"2012","journal-title":"Cell"},{"key":"2022060801065693100_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"2022060801065693100_bib19","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1158\/1078-0432.CCR-16-0610","article-title":"Somatic and germline TP53 alterations in second malignant neoplasms from pediatric cancer survivors","volume":"23","author":"Sherborne","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2022060801065693100_bib20","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.cell.2017.01.020","article-title":"KRAS allelic imbalance enhances fitness and modulates MAP kinase dependence in cancer","volume":"168","author":"Burgess","year":"2017","journal-title":"Cell"},{"key":"2022060801065693100_bib21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ccr.2005.08.011","article-title":"Therapy-induced malignant neoplasms in Nf1 mutant mice","volume":"8","author":"Chao","year":"2005","journal-title":"Cancer Cell"},{"key":"2022060801065693100_bib22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrc2109","article-title":"Hyperactive Ras in developmental disorders and cancer","volume":"7","author":"Schubbert","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"2022060801065693100_bib23","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2350\/14-05-1488-OA.1","article-title":"Early-lethal Costello syndrome due to rare HRAS Tandem Base substitution (c.35_36GC&gt;AA; p.G12E)-associated pulmonary vascular disease","volume":"17","author":"Weaver","year":"2014","journal-title":"Pediatr Dev Pathol"},{"key":"2022060801065693100_bib24","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/s41589-018-0081-9","article-title":"Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer","volume":"14","author":"Donnella","year":"2018","journal-title":"Nat Chem Biol"},{"key":"2022060801065693100_bib25","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/1535-7163.MCT-13-0639","article-title":"Picking the point of inhibition: a comparative review of PI3K\/AKT\/mTOR pathway inhibitors","volume":"13","author":"Dienstmann","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"2022060801065693100_bib26","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.5301\/jbm.5000189","article-title":"Genetic alteration in phosphofructokinase family promotes growth of muscle-invasive bladder cancer","volume":"31","author":"Sun","year":"2016","journal-title":"Int J Biol Markers"},{"key":"2022060801065693100_bib27","doi-asserted-by":"crossref","first-page":"45545","DOI":"10.1038\/srep45545","article-title":"PCTK3\/CDK18 regulates cell migration and adhesion by negatively modulating FAK activity","volume":"7","author":"Matsuda","year":"2017","journal-title":"Sci Rep"},{"key":"2022060801065693100_bib28","doi-asserted-by":"crossref","first-page":"e73987","DOI":"10.1371\/journal.pone.0073987","article-title":"Zygotic G2\u2013M cell cycle arrest induced by ATM\/Chk1 activation and DNA repair in mouse embryos fertilized with hydrogen peroxide-treated epididymal mouse sperm","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"2022060801065693100_bib29","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.3390\/molecules21121730","article-title":"The HK2 dependent \"Warburg effect\" and mitochondrial oxidative phosphorylation in cancer: targets for effective therapy with 3-bromopyruvate","volume":"21","author":"Lis","year":"2016","journal-title":"Molecules"},{"key":"2022060801065693100_bib30","doi-asserted-by":"crossref","first-page":"83602","DOI":"10.18632\/oncotarget.18787","article-title":"Glycolytic reprogramming through PCK2 regulates tumor initiation of prostate cancer cells","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"key":"2022060801065693100_bib31","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1471-2407-14-160","article-title":"Expression of phosphoenolpyruvate carboxykinase linked to chemoradiation susceptibility of human colon cancer cells","volume":"14","author":"Park","year":"2014","journal-title":"BMC Cancer"},{"key":"2022060801065693100_bib32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.imlet.2004.08.013","article-title":"The link between PKCalpha regulation and cellular transformation","volume":"96","author":"Michie","year":"2005","journal-title":"Immunol Lett"},{"key":"2022060801065693100_bib33","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1083\/jcb.200807151","article-title":"Regulation of EphB2 activation and cell repulsion by feedback control of the MAPK pathway","volume":"183","author":"Poliakov","year":"2008","journal-title":"J Cell Biol"},{"key":"2022060801065693100_bib34","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/carcin\/bgi259","article-title":"Reduced expression of EphB2 that parallels invasion and metastasis in colorectal tumours","volume":"27","author":"Guo","year":"2006","journal-title":"Carcinogenesis"},{"key":"2022060801065693100_bib35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1046\/j.1432-1327.1998.2570169.x","article-title":"Localization of phospholipase C delta3 in the cell and regulation of its activity by phospholipids and calcium","volume":"257","author":"Pawelczyk","year":"1998","journal-title":"Eur J Biochem"},{"key":"2022060801065693100_bib36","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.4161\/cc.5.14.3005","article-title":"Regulation of PTEN function as a PIP3 gatekeeper through membrane interaction","volume":"5","author":"Vazquez","year":"2006","journal-title":"Cell Cycle"},{"key":"2022060801065693100_bib37","first-page":"361","article-title":"Activation of conventional and novel protein kinase C isozymes by different diacylglycerol molecular species","volume":"7","author":"Kamiya","year":"2016","journal-title":"Biochem Biophys Rep"},{"key":"2022060801065693100_bib38","doi-asserted-by":"crossref","first-page":"e43761","DOI":"10.1371\/journal.pone.0043761","article-title":"Structure of a novel winged-helix like domain from human NFRKB protein","volume":"7","author":"Kumar","year":"2012","journal-title":"PLoS One"},{"key":"2022060801065693100_bib39","doi-asserted-by":"crossref","first-page":"11283","DOI":"10.1074\/jbc.M111.222505","article-title":"Subunit organization of the human INO80 chromatin remodeling complex: an evolutionarily conserved core complex catalyzes ATP-dependent nucleosome remodeling","volume":"286","author":"Chen","year":"2011","journal-title":"J Biol Chem"},{"key":"2022060801065693100_bib40","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1158\/1541-7786.MCR-18-0327","article-title":"Hyperactivation of MAPK signaling is deleterious to RAS\/RAF-mutant melanoma","volume":"17","author":"Leung","year":"2019","journal-title":"Mol Cancer Res"},{"key":"2022060801065693100_bib41","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.3892\/ijo.2015.2960","article-title":"A novel compound against oncogenic Aurora kinase A overcomes imatinib resistance in chronic myeloid leukemia cells","volume":"46","author":"Long","year":"2015","journal-title":"Int J Oncol"},{"key":"2022060801065693100_bib42","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/1878-0261.12066","article-title":"Cisplatin-resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib","volume":"11","author":"Wang","year":"2017","journal-title":"Mol Oncol"},{"key":"2022060801065693100_bib43","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"key":"2022060801065693100_bib44","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol Cell"},{"key":"2022060801065693100_bib45","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/mc.20628","article-title":"Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways","volume":"49","author":"Chen","year":"2010","journal-title":"Mol Carcinog"},{"key":"2022060801065693100_bib46","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/ng.3990","article-title":"Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers","volume":"49","author":"Blakely","year":"2017","journal-title":"Nat Genet"}],"container-title":["Molecular Cancer Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/mct\/article-pdf\/19\/11\/2382\/1863717\/2382.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/mct\/article-pdf\/19\/11\/2382\/1863717\/2382.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T12:20:26Z","timestamp":1723465226000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/mct\/article\/19\/11\/2382\/92697\/Nf1-Mutant-Tumors-Undergo-Transcriptome-and-Kinome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,1]]},"references-count":46,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,3]]},"published-print":{"date-parts":[[2020,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1535-7163.mct-19-1017","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/1535-7163.c.6542103.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22518735","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22518759","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22518738.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22518735.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22518771","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22518741","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22518765","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22518777","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22518741.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22518744.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22518768","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22518738","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22518768.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22518771.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22518774.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22518759.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22518762","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22518774","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22518780.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22518744","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22518762.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22518777.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22518780","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.22518765.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.c.6542103","asserted-by":"object"}]},"ISSN":["1535-7163","1538-8514"],"issn-type":[{"value":"1535-7163","type":"print"},{"value":"1538-8514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,1]]}}}